Literature DB >> 14569422

The management of osteoporosis following hip fracture: have we improved our care?

Sachin Bahl1, Penelope S Coates, Susan L Greenspan.   

Abstract

To determine if physicians have improved the recognition and treatment of osteoporosis in patients with an acute hip fracture, we performed a retrospective analysis of discharge data from 1995 and 2000 at the University of Pittsburgh Medical Center, a large tertiary care, academic institution. We examined patients admitted with an acute hip fracture in 1995 and 2000 and age- and sex-matched patients admitted with community acquired pneumonia in 2000. Outcomes included age, gender, race, discharge diagnoses (from ICD-9 codes) and discharge medications (from discharge summaries) in all patients. There were 136 acute hip fracture patients (mean age 73+/-18 years) in 1995, 117 acute hip fracture patients (mean age 76+/-16 years) in 2000 and 116 patients with community-acquired pneumonia (mean age 78+/-7 years). Patients admitted in 2000 with an acute hip fracture were more likely to be diagnosed with osteoporosis (18% vs. 4%, P<0.02), more likely to be discharged on calcium (17% vs. 7%, P<0.02) and more likely to be discharged on antiresorptive therapy (15% vs. 2%, P<0.001) than those admitted in 1995. Moreover, patients admitted with community-acquired pneumonia were just as likely to receive calcium, vitamin D or antiresorptive agents at the time of discharge as those with an acute hip fracture in 2000. Patients with a diagnosis of osteoporosis in 2000 were older and more likely to receive antiresorptive agents than those without a diagnosis (29% vs. 11%, P<0.05). None of the patients received a bone mineral density examination while in the hospital. Although there was an improvement in the management of osteoporosis after an acute hip fracture from 1995 to 2000, there was no difference in management of patients with hip fracture versus pneumonia in the year 2000. However, patients with a "diagnosis" of osteoporosis in 2000 were more likely to be discharged on appropriate therapeutic options. We conclude that although we have improved our care of osteoporosis for elderly in general from 1995 to 2000, patients with an acute hip fracture are not receiving any additional treatment unless they have a diagnosis of osteoporosis. Further studies are needed to determine which factors are needed to target patients for appropriate diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14569422     DOI: 10.1007/s00198-003-1492-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  25 in total

1.  The risk of subsequent fractures in community-dwelling men and male veterans with hip fracture.

Authors:  C S Colón-Emeric; R Sloane; W G Hawkes; J Magaziner; S I Zimmerman; C F Pieper; K W Lyles
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

2.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

3.  Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

Authors: 
Journal:  JAMA       Date:  1996-11-06       Impact factor: 56.272

4.  Osteoporosis follow-up after wrist fractures following minor trauma.

Authors:  S A Khan; C de Geus; B Holroyd; A S Russell
Journal:  Arch Intern Med       Date:  2001-05-28

5.  Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures.

Authors:  H Castel; D Y Bonneh; M Sherf; Y Liel
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

6.  Evaluation of osteoporosis treatment in seniors after hip fracture.

Authors:  A G Juby; C M De Geus-Wenceslau
Journal:  Osteoporos Int       Date:  2002-03       Impact factor: 4.507

7.  Osteoporosis intervention following distal forearm fractures: a missed opportunity?

Authors:  Maria-Teresa Cuddihy; Sherine E Gabriel; Cynthia S Crowson; Elizabeth J Atkinson; Claudia Tabini; W Michael O'Fallon; L Joseph Melton
Journal:  Arch Intern Med       Date:  2002-02-25

8.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

9.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 10.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

View more
  10 in total

1.  The management of osteoporosis following hip fracture: how to improve our care.

Authors:  Alexander A Fisher; Michael W Davis; Marc M Budge
Journal:  Osteoporos Int       Date:  2004-07       Impact factor: 4.507

2.  Use of osteoporosis medications in older nursing facility residents.

Authors:  Rollin M Wright
Journal:  J Am Med Dir Assoc       Date:  2007-08-13       Impact factor: 4.669

3.  Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey.

Authors:  Vincenzo Carnevale; Luciano Nieddu; Elisabetta Romagnoli; Elisabetta Bona; Sara Piemonte; Alfredo Scillitani; Salvatore Minisola
Journal:  Osteoporos Int       Date:  2005-11-09       Impact factor: 4.507

4.  Women with hip fracture have a greater rate of decline in bone mineral density than expected: another significant consequence of a common geriatric problem.

Authors:  J Magaziner; L Wehren; W G Hawkes; D Orwig; J R Hebel; L Fredman; K Stone; S Zimmerman; M C Hochberg
Journal:  Osteoporos Int       Date:  2006-04-07       Impact factor: 4.507

Review 5.  The assessment of fracture risk.

Authors:  Aasis Unnanuntana; Brian P Gladnick; Eve Donnelly; Joseph M Lane
Journal:  J Bone Joint Surg Am       Date:  2010-03       Impact factor: 5.284

6.  Osteoporotic fragility fractures in African Americans: under-recognized and undertreated.

Authors:  Neelofar M Alam; Juanita A Archer; Euni Lee
Journal:  J Natl Med Assoc       Date:  2004-12       Impact factor: 1.798

7.  Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture.

Authors:  Carl F Pieper; Cathleen Colon-Emeric; John Caminis; Kathleen Betchyk; Jie Zhang; Cheri Janning; John Shostak; Meryl S LeBoff; Robert R Heaney; Kenneth W Lyles
Journal:  Am J Geriatr Pharmacother       Date:  2007-12

Review 8.  Fracture risk assessment in postmenopausal women.

Authors:  Ronald C Hamdy
Journal:  Rev Endocr Metab Disord       Date:  2010-12       Impact factor: 6.514

9.  Established Osteoporosis and Gaps in the Management: Review from a Teaching hospital.

Authors:  Mir Sadat-Ali; As Al-Omran; Wi Al-Bakr; Md Quamar Azam; Am Tantawy; Aa Al-Othman
Journal:  Ann Med Health Sci Res       Date:  2014-03

10.  Brigham fracture intervention team initiatives for hospital patients with hip fractures: a paradigm shift.

Authors:  Julie Glowacki; Mitchel B Harris; Josef Simon; John Wright; Nikheel S Kolatkar; Thomas S Thornhill; Meryl S Leboff
Journal:  Int J Endocrinol       Date:  2010       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.